Zhejiang Medicine Co. Ltd
Zhejiang Medicine Co., Ltd. (浙江医药股份有限公司) is a Chinese pharmaceutical manufacturer (Shanghai SE: 600216) producing APIs, finished preparations, fat-soluble vitamins, carotenoids, antibiotics, and aroma ingredients for global pharmaceutical, food, and feed companies via direct B2B sales.
- Company typePublic
- Founded1997
- HeadquartersShaoxing, China
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Zhejiang Medicine Co. Ltd does
Zhejiang Medicine Co., Ltd. (浙江医药股份有限公司) is a large-scale joint-stock pharmaceutical company headquartered in Shaoxing, Zhejiang, China, listed on the Shanghai Stock Exchange under stock code 600216. Established in May 1997 through the merger of three predecessor pharmaceutical companies, the company manufactures and sells a diversified portfolio spanning Active Pharmaceutical Ingredients (APIs), pharmaceutical preparations (tablets, capsules, soft capsules, injections), human and animal nutrition products, and aroma ingredients. Core therapeutic and nutritional categories include fat-soluble vitamins (A, D3, synthetic and natural E), carotenoids (beta-carotene, lycopene, lutein, canthaxanthin), glycopeptide and quinolone antibiotics (vancomycin hydrochloride, teicoplanin, levofloxacin, linezolid, nemonoxacin), coenzyme Q10 via fermentation, diabetes APIs (sitagliptin, empagliflozin, miglitol), and a new line of monoterpene aroma ingredients (citronellol, linalool, geraniol, citral).
The company's underlying technology rests on two specialized platforms — industrial green chemistry and microencapsulation of active ingredients for vitamin products — supported by 563 domestic and 164 international invention patents, seven professional research institutes with nearly 200 scientific researchers, and the Shanghai Laiyi Biological Drug R&D Center co-founded with China Pharmaceutical University and Shanghai Jiaotong University. Manufacturing is distributed across the Changhai Biological industrial park in Shaoxing, Xinchang Pharmaceutical Factory, and multiple wholly-owned subsidiaries including Zhejiang NovoCodex Biopharmaceuticals and Zhejiang Novus Pharmaceuticals, with international operations via ZMUC, INC. (US) and ZMC-Europe GmbH.
Zhejiang Medicine operates a B2B enterprise sales model through dedicated international trade departments (animal nutrition, raw materials/intermediates, human nutrition) and domestic wholesale and healthcare product divisions. Revenue is generated through direct sales of pharmaceutical and nutritional ingredients to global pharmaceutical, food, and feed manufacturers, with FDA, EU EDQM, PMDA, MFDS, and NMPA certifications enabling access to regulated markets worldwide. The company participates in major industry exhibitions (CPHI, FIC) for demand generation. As of end-2018, total assets were 10 billion yuan with 960 million yuan registered capital; the company is ranked 50th in the 2025 China Pharmaceutical Industry Top 100.
Zhejiang Medicine Co. Ltd firmographics
Firmographics- Name
- Zhejiang Medicine Co. Ltd
- Legal name
- 浙江医药股份有限公司
- Website
- https://zmc.top
- Company type
- Public
- Founded year
- 1997
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Zhejiang Medicine Co., Ltd. (浙江医药股份有限公司) is a Chinese pharmaceutical manufacturer (Shanghai SE: 600216) producing APIs, finished preparations, fat-soluble vitamins, carotenoids, antibiotics, and aroma ingredients for global pharmaceutical, food, and feed companies via direct B2B sales.
- Ownership category
- akta.pro rank
Zhejiang Medicine Co. Ltd industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Antioxidants & Phytochemicals (Carotenoids, Tocopherols, Flavonoids, CoQ10, Resveratrol) (AFAJAKAI)
- akta.pro secondary industries
- Vitamins & Minerals (Single Nutrients) (CRADAGAB), Generic Hospital & Institutional Products (HLAIABAL), Personal Care & Cosmetic Ingredients (IMAEABAJ)
Keywords
Where Zhejiang Medicine Co. Ltd is headquartered
LocationHeadquarters
- HQ city
- Shaoxing
- HQ country
- China
- HQ region
- Asia
Offices4 records
Markets served
Zhejiang Medicine Co. Ltd business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure
Revenue model
- Pharmaceutical Products Manufacturing and Sales: Manufacturing and sale of pharmaceutical products including APIs, intermediate products, preparations, health foods, human nutrition products, animal nutrition products, and aroma ingredients. Revenue from stock market listing on Shanghai Stock Exchange.
- Product Export and International Trade: Export of pharmaceutical products to international markets with FDA, EU, and other certifications. Products include vancomycin hydrochloride, teicoplanin, levofloxacin, and various vitamins.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | B2B enterprise pricing for pharmaceutical products |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
Zhejiang Medicine Co. Ltd product offering
Product offeringCore offering
Zhejiang Medicine Co., Ltd. manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs) and intermediates (vancomycin, teicoplanin, levofloxacin, linezolid, minocycline, daptomycin), finished dosage preparations (tablets, capsules, soft capsules, injections), fat-soluble vitamins (A, D3, E), carotenoids (beta-carotene, lutein, lycopene, canthaxanthin), coenzyme Q10, biotin, and aroma ingredients (citronellal, linalool, geraniol). Products are sold globally to pharmaceutical manufacturers, food/nutrition companies, and animal feed companies with FDA, EU, and other international certifications.
Product overview
Zhejiang Medicine Co., Ltd. is a large-scale joint-stock pharmaceutical company established in May 1997, listed on the Shanghai Stock Exchange (stock code: 600216). The company operates a diversified portfolio organized across multiple product categories: (1) Pharmaceutical Preparations including tablets, capsules, soft capsules, and injections; (2) Active Pharmaceutical Ingredients (APIs) and intermediates including antibiotics (vancomycin, teicoplanin, levofloxacin, linezolid, minocycline, daptomycin), vitamins, and specialty chemicals; (3) Human and Animal Nutrition products featuring fat-soluble vitamins (A, D, E), carotenoids (beta-carotene, lutein, lycopene, canthaxanthin), coenzyme Q10, and biotin; (4) Aroma Ingredients including citronellal, citronellol, geraniol, linalool, and their derivatives for flavor and fragrance applications. The company maintains nine major subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Changhai Biological Company, and operates research centers in Shanghai and Shaoxing with over 200 R&D personnel.
Differentiator
Problem solved
Functional benefit
Products and services
- Vitamin A
Quantifiable outcome
- Ranked 50th in 2025 China Pharmaceutical Industry Top 100 by revenue
- +3 more outcomes
Companies that use Zhejiang Medicine Co. Ltd
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles4 records
Zhejiang Medicine Co. Ltd technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Zhejiang Medicine Co. Ltd partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered major, core and minor.
- AmbrxmajorAmbrx and Zhejiang Medicine announced agreement to develop monoclonal antibody drug conjugates (ADCs) for the treatment of breast cancer. This strategic partnership leverages Ambrx's ADC technology with Zhejiang Medicine's pharmaceutical manufacturing capabilities.
- Nanjing University of Technology (Academician Ouyang Pingkai team)coreAcademician Expert Workstation established at Zhejiang Pharmaceutical Co., Ltd. with the expert team of Academician Ouyang Pingkai for pharmaceutical technology innovation and research.
- Zhejiang University of Technology (Academician Zheng Yuguo team)coreAcademician Expert Workstation at Zhejiang Changhai Pharmaceutical Co., Ltd. with the expert team of Academician Zheng Yuguo for industry-university-research cooperation.
- China Pharmaceutical UniversitycoreLong-term cooperation including joint establishment of Shanghai Laiyi Biological Drug Research and Development Center and production-university-research cooperation projects. Signed cooperation project for development of new drugs against gram-negative drug-resistant bacteria with Professor Mao Wenwei of Shanghai Jiaotong University.
- Shanghai Jiaotong UniversitycoreCo-founded Shanghai Laiyi Biological Drug Research and Development Center with China Pharmaceutical University. Signed cooperation project for new drug development against drug-resistant bacteria.
- China Pharmaceutical University - Institute of Innovative Drugs (Hangzhou)coreSigned production-university-research cooperation project during the unveiling ceremony of Institute of Innovative Drugs (Hangzhou). Vice President Kong Lingyi and President Lu Chunlei signed the agreement on behalf of both parties.
- China Pharmaceutical UniversitymajorGranted as 'China Pharmaceutical University High-Quality Employment Base for Graduates'. Chairman Li Chunbo appointed as Vice President of China Pharmaceutical University International Medical Business School Alumni Association. Deepening cooperation in talent cultivation and scientific research.
- East Kentucky University (EKU)minorChairman Li Chunbo received honorary doctorate of law from EKU in 2011. Cooperation agreement signed in 2010. Multiple visits by EKU delegations for academic and business cooperation discussions.
- Zhejiang Provincial Drug and Cosmetic Review CentermajorCooperation to establish 'Government-Enterprise Service Space Station' - first such cooperation in Shaoxing. Jointly organized training on post-approval drug changes and regulatory affairs to support pharmaceutical industry development.
Scale indicators8 records
Recent moves11 records
Zhejiang Medicine Co. Ltd competitors and assessment
Company assessmentBroad incumbents
- Lonza Group: Swiss API and biopharmaceutical contract manufacturer. Comparable in fermentation-derived APIs (CoQ10 adjacent) and pharma manufacturing services with strong regulatory positioning.
- CSPC Pharmaceutical Group: Large Hong Kong-listed Chinese pharma group covering APIs, finished formulations, and innovative biologics. Broader portfolio than ZMC but operates in overlapping APIs and antibiotic franchises.
- DSM-Firmenich: Global leader in vitamins, carotenoids, and nutritional ingredients plus flavors and fragrances. Competes head-to-head with ZMC in beta-carotene, Vitamin E, and CoQ10 while also serving as customer benchmark.
- BASF: Global chemical major with significant vitamins and APIs business (BASF Nutrition & Health). Competes in vitamin E, carotenoids, and pharma ingredients on global scale.
- IFF (International Flavors & Fragrances): Global flavor and fragrance ingredients producer. Comparable on ZMC's aroma ingredient segment (citronellol, linalool, geraniol) where IFF is a downstream customer/competitor.
Direct peers
- Garden Biochemical (High-Tech): Chinese manufacturer of CoQ10, vitamins, and carotenoids. Direct competitor in fermentation-based nutraceutical ingredients (especially CoQ10) and beta-carotene, with overlapping customer base in nutrition and supplement industries.
- Zhejiang NHU Company: Major Chinese manufacturer of vitamins (especially Vitamin E, A, D3), flavor and fragrance ingredients, and APIs. Closest direct comparable given shared Zhejiang base, identical vitamin product mix, and similar nutraceutical-ingredient strategy.
- Northeast Pharmaceutical Group: Large Chinese producer of vitamins (especially Vitamin C) and APIs. Comparable in scale, product overlap (vitamins and antibiotics), and customer base in nutrition and pharma ingredients.
- Zhejiang Hisun Pharmaceutical: Zhejiang-based pharmaceutical manufacturer producing APIs and finished formulations with FDA-approved facilities. Comparable on API production, international certifications, and integrated pharma value chain.
- Zhejiang Huahai Pharmaceutical: Zhejiang-based API manufacturer with strong global regulatory footprint (FDA, EDQM) and focus on cardiovascular, anti-retroviral, and specialty APIs. Directly comparable on API manufacturing, regulatory certifications, and export channels.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Zhejiang Medicine Co. Ltd social profiles
Digital presenceZhejiang Medicine Co. Ltd financial estimates
Financial estimateRevenue estimate
Valuation estimate
Zhejiang Medicine Co. Ltd leadership team
Management profileNumber of profiles
Profiles18 records
Zhejiang Medicine Co. Ltd subsidiaries and ownership
Company hierarchySubsidiaries18 records
Zhejiang Medicine Co. Ltd funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Zhejiang Medicine Co. Ltd M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Zhejiang Medicine Co. Ltd
What does Zhejiang Medicine Co. Ltd do?
Zhejiang Medicine Co., Ltd. manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs) and intermediates (vancomycin, teicoplanin, levofloxacin, linezolid, minocycline, daptomycin), finished dosage preparations (tablets, capsules, soft capsules, injections), fat-soluble vitamins (A, D3, E), carotenoids (beta-carotene, lutein, lycopene, canthaxanthin), coenzyme Q10, biotin, and aroma ingredients (citronellal, linalool, geraniol). Products are sold globally to pharmaceutical manufacturers, food/nutrition companies, and animal feed companies with FDA, EU, and other international certifications.
Is Zhejiang Medicine Co. Ltd a public or private company?
Zhejiang Medicine Co. Ltd is a public company. It is classified as public and is currently operating.
When was Zhejiang Medicine Co. Ltd founded?
Zhejiang Medicine Co. Ltd was founded in 1997. It employs 11 to 50 people.
Where is Zhejiang Medicine Co. Ltd based?
Zhejiang Medicine Co. Ltd is headquartered in Shaoxing, China, in the Asia region.
How does Zhejiang Medicine Co. Ltd make money?
Two revenue lines are on record. Pharmaceutical Products Manufacturing and Sales are the primary driver. The others are product Export and International Trade.
Who are Zhejiang Medicine Co. Ltd's main competitors?
Broad incumbents on record are Lonza Group, CSPC Pharmaceutical Group, DSM-Firmenich, BASF and IFF (International Flavors & Fragrances). Direct peers are Garden Biochemical (High-Tech), Zhejiang NHU Company, Northeast Pharmaceutical Group, Zhejiang Hisun Pharmaceutical and Zhejiang Huahai Pharmaceutical.
Does Zhejiang Medicine Co. Ltd have an API?
No public API is recorded for Zhejiang Medicine Co. Ltd.
What industry is Zhejiang Medicine Co. Ltd in?
Zhejiang Medicine Co. Ltd's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is AFAJAKAI, Antioxidants & Phytochemicals (Carotenoids, Tocopherols, Flavonoids, CoQ10, Resveratrol), with a secondary code of CRADAGAB, Vitamins & Minerals (Single Nutrients). Its NAICS code is 325412 and its SIC code is 2834.